Relay Therapeutics, Inc. 致力於轉變藥物發現流程,初期專注於提升靶向腫瘤學和遺傳疾病適應症中的小分子治療藥物發現。公司總部位於麻薩諸塞州劍橋市,目前聘有261名全職員工。该公司於2020年7月16日上市。其Dynamo平台整合了一系列計算與實驗方法,旨在針對過去難以處理或未被充分解決的蛋白質靶點開發藥物。公司目前領先的產品候選藥物為RLY-2608。公司正在推進一個藥物候選管道,以針對精準腫瘤學和遺傳疾病中的靶點,其中包括RLY-2608。RLY-2608是一種別構調控、泛突變型且同工酶選擇性的磷脂醯肌醇3激酶α(PI3Kα)抑制劑,目前處於臨床開發階段。該公司領先的研發項目致力於發現與開發針對PI3Kα突變選擇性抑制劑。
How did RLAY's recent EPS compare to expectations?
The most recent EPS for Relay Therapeutics Inc is $-0.32, 未達預期 expectations of $-0.41.
How did Relay Therapeutics Inc RLAY's revenue perform in the last quarter?
Relay Therapeutics Inc revenue for the last quarter is $-0.32
What is the revenue estimate for Relay Therapeutics Inc?
According to 9 of Wall street analyst, the revenue estimate of Relay Therapeutics Inc range from $525.0K to $0.0
What's the earning quality score for Relay Therapeutics Inc?
Relay Therapeutics Inc has a earning quality score of B/43.930626. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Relay Therapeutics Inc report earnings?
Relay Therapeutics Inc next earnings report is expected in 2026-05-27
What are Relay Therapeutics Inc's expected earnings?
Relay Therapeutics Inc expected earnings is $5.06M, according to wall-street analysts.
Did Relay Therapeutics Inc beat earnings expectations?
Relay Therapeutics Inc recent earnings of $7.0M 超出預期 expectations.